FUM — Futura Medical Share Price
Last trade - 00:00- £105.06m
- £97.34m
- £3.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.18 | ||
| Price to Tang. Book | 19.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 33.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -127.15% | ||
| Return on Equity | -127.75% | ||
| Operating Margin | -224.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.03 | n/a | n/a | n/a | 3.1 | 9.52 | 16.43 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
Directors
- John Clarke NEC (71)
- James Barder CEO (58)
- Angela Hildreth FID
- Ken James EDR (66)
- Jeffrey Needham NED (65)
- Andrew Unitt NED (64)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 25th, 2001
- Public Since
- July 10th, 2006
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 301,449,451
- Address
- 40 Occam Road, GUILDFORD, GU2 7YG
- Web
- https://www.futuramedical.com/
- Phone
- +44 1483685670
- Contact
- James Barder
- Auditors
- Grant Thornton UK LLP
Latest News for FUM
Upcoming Events for FUM
Futura Medical PLC Annual Shareholders Meeting
Futura Medical PLC Annual Shareholders Meeting
Half Year 2024 Futura Medical PLC Earnings Release
Similar to FUM
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 20:45 UTC, shares in Futura Medical are trading at 34.85p. This share price information is delayed by 15 minutes.
Shares in Futura Medical last closed at 34.85p and the price had moved by -32.72% over the past 365 days. In terms of relative price strength the Futura Medical share price has underperformed the FTSE All Share Index by -36.82% over the past year.
The overall consensus recommendation for Futura Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Futura Medical does not currently pay a dividend.
Futura Medical does not currently pay a dividend.
Futura Medical does not currently pay a dividend.
To buy shares in Futura Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 34.85p, shares in Futura Medical had a market capitalisation of £105.06m.
Here are the trading details for Futura Medical:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: FUM
Based on an overall assessment of its quality, value and momentum Futura Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Futura Medical is 128.00p. That is 267.29% above the last closing price of 34.85p.
Analysts covering Futura Medical currently have a consensus Earnings Per Share (EPS) forecast of -£0.01 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Futura Medical. Over the past six months, its share price has outperformed the FTSE All Share Index by +11.13%.
As of the last closing price of 34.85p, shares in Futura Medical were trading -5.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Futura Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 34.85p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Futura Medical's management team is headed by:
- John Clarke - NEC
- James Barder - CEO
- Angela Hildreth - FID
- Ken James - EDR
- Jeffrey Needham - NED
- Andrew Unitt - NED